ES2555778T3 - Mejora de la biodisponibilidad de principios activos con función amidina en medicamentos - Google Patents

Mejora de la biodisponibilidad de principios activos con función amidina en medicamentos Download PDF

Info

Publication number
ES2555778T3
ES2555778T3 ES07785614.4T ES07785614T ES2555778T3 ES 2555778 T3 ES2555778 T3 ES 2555778T3 ES 07785614 T ES07785614 T ES 07785614T ES 2555778 T3 ES2555778 T3 ES 2555778T3
Authority
ES
Spain
Prior art keywords
bioavailability
medicines
improvement
active ingredients
amidine function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07785614.4T
Other languages
English (en)
Inventor
Bernd Clement
Christiane Reeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dritte Patentportfolio Beteiligungs GmbH and Co KG
Original Assignee
Dritte Patentportfolio Beteiligungs GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dritte Patentportfolio Beteiligungs GmbH and Co KG filed Critical Dritte Patentportfolio Beteiligungs GmbH and Co KG
Application granted granted Critical
Publication of ES2555778T3 publication Critical patent/ES2555778T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Empleo de N,N`-dihidroxiamidina (I) de la fórmula**Fórmula** como substituto de una función amidina de un producto farmacéutico en medicamentos para la mejora de la biodisponibilidad del producto farmacéutico.

Description

imagen1
imagen2
imagen3

Claims (1)

  1. imagen1
ES07785614.4T 2006-07-21 2007-07-10 Mejora de la biodisponibilidad de principios activos con función amidina en medicamentos Active ES2555778T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006034256 2006-07-21
DE102006034256A DE102006034256A1 (de) 2006-07-21 2006-07-21 Verbesserung der Bioverfügbarkeit von Wirkstoffen mit Amidinfunktion in Arzneimitteln
PCT/DE2007/001216 WO2008009264A1 (de) 2006-07-21 2007-07-10 Verbesserung der bioverfügbarkeit von wirkstoffen mit amidinfunktion in arzneimitteln

Publications (1)

Publication Number Publication Date
ES2555778T3 true ES2555778T3 (es) 2016-01-08

Family

ID=38721771

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07785614.4T Active ES2555778T3 (es) 2006-07-21 2007-07-10 Mejora de la biodisponibilidad de principios activos con función amidina en medicamentos

Country Status (19)

Country Link
US (1) US20090270440A1 (es)
EP (2) EP2987784A1 (es)
JP (1) JP2009544588A (es)
KR (1) KR20090075792A (es)
CN (2) CN104644619A (es)
AU (1) AU2007276526B2 (es)
CA (2) CA2658434C (es)
CY (1) CY1116941T1 (es)
DE (1) DE102006034256A1 (es)
DK (1) DK2046732T5 (es)
ES (1) ES2555778T3 (es)
HK (2) HK1210694A1 (es)
HU (1) HUE025801T2 (es)
PL (1) PL2046732T3 (es)
PT (1) PT2046732E (es)
SG (1) SG173401A1 (es)
SI (1) SI2046732T1 (es)
WO (1) WO2008009264A1 (es)
ZA (1) ZA200901212B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008007440A1 (de) * 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Aminosäurederivate als Arzneistoffe
DE102008007381A1 (de) 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten
US9662308B2 (en) 2008-02-01 2017-05-30 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg Orally bioavailable pentamidine prodrugs for the treatment of diseases
DE102008061247A1 (de) 2008-12-10 2010-06-24 Christian-Albrechts-Universität Zu Kiel Inhibitoren der Dimethylarginin Dimethylaminohydrolase
DE102009004204A1 (de) * 2009-01-09 2010-07-15 Christian-Albrechts-Universität Zu Kiel Verfahren zur verbesserten Bioaktivierung von Arzneistoffen
CN103420994B (zh) * 2012-05-24 2016-04-06 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103864710B (zh) * 2014-03-24 2016-05-25 西安近代化学研究所 一种3-(3-氨基呋咱-4-基)-5-甲基-5-取代-4-羟基-4h,5h-1,2,4-恶二唑化合物的合成方法
CN103951660B (zh) * 2014-03-24 2016-07-06 西安近代化学研究所 一种恶二唑化合物的合成方法
GB201615693D0 (en) 2016-09-15 2016-11-02 Combinatorx Infection Ltd Combinations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4321444A1 (de) * 1993-06-28 1995-01-05 Bernd Prof Dr Clement Pharmazeutische Zubereitung
US5723495A (en) * 1995-11-16 1998-03-03 The University Of North Carolina At Chapel Hill Benzamidoxime prodrugs as antipneumocystic agents
US6740682B2 (en) * 1997-08-29 2004-05-25 Tularik Limited Meta-benzamidine derivatives as serine protease inhibitors
US6291514B1 (en) * 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
US7157596B2 (en) * 2000-09-08 2007-01-02 Dendreon Corporation Inhibitors of serine protease activity of matriptase or MTSP1
US20040082585A1 (en) * 2001-10-03 2004-04-29 Pharmacia Corporation Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade

Also Published As

Publication number Publication date
KR20090075792A (ko) 2009-07-09
ZA200901212B (en) 2010-02-24
HUE025801T2 (en) 2016-04-28
PT2046732E (pt) 2016-01-06
DE102006034256A1 (de) 2008-01-31
CA2777173A1 (en) 2008-01-24
AU2007276526A1 (en) 2008-01-24
EP2046732A1 (de) 2009-04-15
SI2046732T1 (sl) 2016-02-29
EP2987784A1 (de) 2016-02-24
CA2658434A1 (en) 2008-01-24
WO2008009264A1 (de) 2008-01-24
US20090270440A1 (en) 2009-10-29
HK1210694A1 (en) 2016-05-06
JP2009544588A (ja) 2009-12-17
EP2046732B1 (de) 2015-09-09
PL2046732T3 (pl) 2016-02-29
CN104644619A (zh) 2015-05-27
AU2007276526B2 (en) 2011-08-11
SG173401A1 (en) 2011-08-29
CN101506151A (zh) 2009-08-12
CA2658434E (en) 2008-01-24
DK2046732T3 (en) 2015-11-16
HK1221455A1 (zh) 2017-06-02
CA2658434C (en) 2012-08-14
CY1116941T1 (el) 2017-04-05
DK2046732T5 (en) 2016-01-04

Similar Documents

Publication Publication Date Title
ES2601127T3 (es) Derivado de pirazol y su uso con fines médicos
ES2500067T3 (es) Compuesto bicíclico y uso del mismo para fines médicos
AR114143A2 (es) Formulaciones de comprimidos revestidos
CY1120377T1 (el) Στερεη φαρμακευτικη δοσολογικη φαρμακοτεχνικη μορφη που περιεχει λοπιναβιρη
ATE555768T1 (de) Behälter mit mehreren fächern
ES2494316T3 (es) Ingrediente activo novedoso en cicatrización y uso del mismo
ES2527242T3 (es) Composiciones que comprenden un germinante y un agente antimicrobiano
MX2010004222A (es) Formulaciones solidas de compuestos cristalinos.
AR059390A1 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos
ECSP099451A (es) Compuestos de urea policíclicos antibacterianos
ES2525918T3 (es) Proceso para la fabricación de Nicorandil
EP1985287A3 (en) Pharmaceutical Excipient Complex
DOP2010000299A (es) Uso de dronedarona para la preparacion de un medicamento para uso en la prevencion de la hospitalizacion cardiovascular o de la mortalidad
CR11641A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
UY30544A1 (es) Compuestos de pirrolo-piperidina y sales farmacéuticametne aceptables de los mismos, procesos de fabricacion, composiciones y aplicaciones
DOP2012000050A (es) Nuevas composiciones de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil] piperazina
FR2983409B1 (fr) Comprime susceptible de lutter contre le detournement par voie injectable
UY29561A1 (es) Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
CY1108231T1 (el) Σταθερη στερεα δοσολογικη μορφη περιλαμβανουσα δεσμοπρεσσινη
ES2581331T3 (es) Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática
ES2550608T3 (es) Composición nutritiva para la curación de las heridas
ES2616882T3 (es) Composición farmacéutica que comprende un agonista del receptor de adenosina A3 (IB-MECA/CF-101) para el tratamiento de la psoriasis
CL2009000257A1 (es) Uso de imidazolinas 1,3 sustituidas y de sus sales fisiologicamente compatibles para el tratamiento del sindrome metabolico.
DE602008002371D1 (de) Pharmazeutische zusammensetzung mit candesartan-cilexetil